Doctiplus - We are allways here!
Dementia & Alzheimer's
Weekly Report
- 14 new clinical trials registered across 7 countries.
- 957 trials actively recruiting patients worldwide.
- Notable trial: China HEalthy Aging and Dementia Study (HEAD) (20000 patients).
- 1,326 new research papers published.
- Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
14 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study Dementia & Alzheimer's · Fudan University (NCT07923812) | Other | Recruiting | 3,000 | China |
| 02 | Lisdexamfetamine For the Treatment of Conduct Disorder in Children Dementia & Alzheimer's · Orygen (NCT07923617) | Phase 2 | Not Yet Recruiting | 30 | N/A |
| 03 | BioMIND Biospecimen Repository Dementia & Alzheimer's · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (NCT07912736) | Other | Enrolling By Invitation | 1,000 | Canada |
| 04 | Weighted Blankets for Agitation in Adults in the Intensive Care Unit Dementia & Alzheimer's · Anmed Health (NCT07920497) | Other | Active Not Recruiting | 200 | United States |
| 05 | Exercise in Alzheimer's Disease: Functional Biomarkers Dementia & Alzheimer's · European University Miguel de Cervantes (NCT07918417) | Other | Not Yet Recruiting | 48 | Spain |
| 06 | China HEalthy Aging and Dementia Study (HEAD) Dementia & Alzheimer's · Fudan University (NCT07912710) | Other | Recruiting | 20,000 | China |
| 07 | The Effectiveness of Comic-based Learning Materials on Nursing Students' Knowledge, Attitudes, and Confidence in Dementia Care Dementia & Alzheimer's · Taipei Medical University (NCT07922109) | Other | Not Yet Recruiting | 84 | N/A |
| 08 | Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE) Dementia & Alzheimer's · Chinese University of Hong Kong (NCT07917182) | Other | Not Yet Recruiting | 1,600 | China |
| 09 | Prospective Research on Identification of Dementia in Early Stages (P.R.I.D.E) Dementia & Alzheimer's · Don Mottola Medical Center (NCT07918638) | Other | Not Yet Recruiting | 1,000 | N/A |
| 10 | Small Monetary Incentives for Digital Cognitive Training Adherence in Community-Dwelling Older Adults Dementia & Alzheimer's · Xuanwu Hospital, Beijing (NCT07913243) | Other | Not Yet Recruiting | 110 | China |
| 11 | Effects of Transcranial Direct Current Stimulation on Cyberaggressive Behaviour in Adults Dementia & Alzheimer's · Nanyang Technological University (NCT07908862) | Other | Not Yet Recruiting | 159 | Singapore |
| 12 | Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME) Dementia & Alzheimer's · Istituti Clinici Scientifici Maugeri SpA (NCT07911878) | Other | Recruiting | 300 | Italy |
| 13 | Music Listening for Chronic Pain in Adults With Early-Stage Dementia Dementia & Alzheimer's · Florida State University (NCT07918534) | Other | Not Yet Recruiting | 40 | N/A |
| 14 | Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants Dementia & Alzheimer's · Neurelis, Inc. (NCT07921966) | Phase 1 | Not Yet Recruiting | 24 | N/A |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| donepezil | Death | 208 |
| memantine | Death | 129 |
| rivastigmine | Death | 292 |
| galantamine | Fall | 32 |
| lecanemab | Amyloid Related Imaging Abnormality-oedema/effusion | 204 |
Recalls & safety notices
FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Pomegranate Seed Oil Biologically Engineered Lactobacillus Extracellular Vesicles with Enhanced Yield and Brain Delivery via ApoE-Enriched Protein Corona.
View abstractPURPOSE: The blood-brain barrier (BBB) is a major bottleneck for nanomedicine-based treatment of central nervous system (CNS) disorders. -derived extracellular vesicles (LEV) are promising biocompatible nanocarriers, but their low production yield and limited BBB permeability hinder their development. We hypothesized that stimulation of with pomegranate seed oil (PSO), or its nanoemulsion (PSO NE), could remodel the LEV membrane to simultaneously enhance vesicle production and brain accumulation. METHODS: was stimulated with PSO or PSO NE to generate engineered LEV. Lipidomic and proteomic analyses were performed to characterize membrane remodeling and plasma protein corona formation. Oleuropein (OL) was loaded into different LEV formulations, and their BBB permeability and brain accumulation were evaluated in vivo. The anti-amyloid β (Aβ) aggregation activity and biocompatibility of the engineered LEVs were also assessed. RESULTS: PSO and PSO NE increased LEV production by approximately 3- and 5-fold, respectively, while markedly remodeling their membrane composition, with enrichment of phospholipids, triglycerides, and apolipoproteins. Upon exposure to plasma, the remodeled LEVs spontaneously acquired an apolipoprotein E (ApoE)-rich protein corona, facilitating BBB transport through low-density lipoprotein receptor (LDLR)-mediated transcytosis. Accordingly, OL-loaded LEV-PSO and LEV-PSO NE achieved 5-7-fold higher brain exposure than free OL, compared with only a 1.17-fold increase for conventional OL@LEV. Both native and OL-loaded LEVs inhibited Aβ aggregation, with OL-loaded formulations showing stronger activity. Repeated administration for 14 days demonstrated good biocompatibility and significantly increased BBB LDLR expression following LEV-PSO and LEV-PSO NE treatment. CONCLUSION: PSO-mediated membrane engineering substantially improves LEV production and BBB transport through protein-corona modulation, providing a scalable and versatile platform for CNS drug delivery. |
International journal of nanomedicine | 2026 | PubMed |
| 02 |
Dilated Virchow-Robin Space and Cognitive Impairment in People With Parkinson's Disease: A Systematic Review.
View abstractVirchow-Robin space (VRS) is characterized by small cavitary or cystic structures in the brain that represent morphological markers of altered interstitial fluid dynamics within the perivascular (glymphatic) pathway, originating from small vessels in the subarachnoid space and penetrating the brain. Their dilation has been associated with altered clinical status in Parkinson's disease (PD). The present study aims to review the reported relations between dilated VRS (dVRS) and cognitive impairment in patients with PD. A total of 71 articles were identified through database searching, and after reviewing based on the eligibility criteria, 16 studies were selected. Across the directly relevant PD studies, dVRS burden was associated with lower scores on some cognitive tests in some, but not all, cohorts; several studies reported null or only indirect associations. The most commonly used assessment tool was Montreal Cognitive Assessment (MoCA); the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), Seoul Neuropsychological Screening Battery (SNSB), and Parkinson Neuropsychometric Dementia Assessment (PANDA) were also used across the included studies. Overall, the presence of the dVRS in basal ganglia in patients with PD was frequently associated with the vascular risk factors, and the resulting mechanical mass effect (local compression and displacement of adjacent neural structures by the dilated, fluid-filled spaces), impaired waste clearance, and vascular impact have been proposed as pathways potentially relating dVRS to cognitive status in these patients. Cognitive decline in the case of basal ganglia dVRS is shown to be associated with crossing inferior fronto-occipital and inferior longitudinal fasciculus fibers. |
Radiology research and practice | 2026 | PubMed |
| 03 |
Gut microbiome depletion aggravates glial-mediated Alzheimer's disease pathology through inflammatory, metabolic, and proteostatic dysregulation.
View abstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by chronic neuroinflammation, metabolic dysfunction, and impaired proteostasis. Emerging evidence suggests that the gut microbiome influences brain function through the gut-brain axis; however, the mechanisms by which this communication affects AD pathology remain poorly understood. In this study, we used humanized AD models expressing human AD-related transgenes in glial cells to investigate how glial AD pathology influences the gut microbiome and how microbiome depletion affects behavior and disease progression. Our findings revealed significant alterations in the abundance of several gut microbial taxa, including , , , , , , and , suggesting a potential interaction between the gut microbiome and AD progression. To further define the role of the gut microbiome in AD progression, we treated with antibiotics to achieve substantial microbiome depletion (SMD) and evaluated the resulting behavioral, physiological, and molecular changes. Compared with conventional controls, flies with SMD exhibited enhanced inflammatory signaling and cell death, impaired autophagy, lipid dysregulation, and increased accumulation of amyloid -42 (a42) and phospho-tau (pTau), with the extent of these changes varying among the different humanized AD models. These molecular alterations further exacerbated sleepcircadian disruption, altered locomotor performance, and worsened learning and memory deficits. Furthermore, we demonstrated a link between enhanced neuroinflammation and the accumulation of a42, pTau, and amyloid precursor protein (APP) proteins. Collectively, our findings demonstrate that gut microbiome depletion aggravates glial-mediated AD pathology through the coordinated disruption of inflammatory, metabolic, and proteostatic pathways, ultimately leading to behavioral dysfunction. These results identify the gut microbiome as a critical regulator of glial homeostasis and provide new insights into its contribution to the progression of neurodegenerative disorders. |
Gut microbes | 2026 Dec 31 | PubMed |
| 04 |
In vivo assessment of brain microstructure in patients with Huntington's disease using quantitative MRI.
View abstractOBJECTIVES: Using multiparametric mapping (MPM), we assessed the integrity of cortical and subcortical regions across different stages of Huntington's disease (HD), relating the derived findings to genetic modifiers and clinical measures. METHODS: Sixteen premanifest patients with HD (PwHD), ten manifesting PwHD (PwHD), and forty-two healthy controls (HC) underwent clinical examinations and a 3 T imaging. We derived quantitative MPM maps to perform voxel-based quantification (VBQ) and voxel-based morphometry (VBM). We assessed group differences by combining PwHD and PwHD (PwHD) and by comparing PwHD and PwHD with age- and sex-matched HC. Using correlation analysis, we investigated the link between MPM-derived findings, CAG repeat length, and clinical scores. RESULTS: PwHD presented with reductions in all four quantitative MPM maps across the bilateral caudate nucleus and the frontal, parietal, temporal, and occipital gyri. We observed spatial overlap between VBQ- and VBM-derived findings, demonstrating widespread volume loss in PwHD. PwHD showed reductions in certain quantitative maps within the frontal and temporal regions. Reduced MPM values correlated with clinical scores of HD severity. INTERPRETATION: The observed reductions across four MPM modalities in PwHD are consistent with demyelination and neuronal loss, as supported by widespread volume loss. The reductions observed in PwHD indicate early demyelination and inflammation. In this study, we demonstrated the utility and clinical relevance of MPM for detecting microstructural alterations across different stages of HD. MPM can serve as a non-invasive biomarker of neurodegeneration in HD, providing insight into the pathological events underlying the observed neuronal loss. |
Journal of neurology | 2026 Nov 7 | PubMed |
| 05 |
Cognitive impairment: Delirium and dementia for oncologists.
View abstractCognitive function is an important consideration in the assessment and management of older adults with cancer. The development of cancer and cognitive impairment share common risk factors associated with the ageing process. Furthermore, older adults with cancer and cognitive problems are more likely to encounter adverse outcomes. This review by the Young International Society of Geriatric Oncology is divided into the following core sections: cognitive screening, approach to the older adult with pre-existing cognitive impairment, and approach to the older adult presenting with declining cognition. It aims to provide oncologists treating older adults with key considerations when it comes to cognition in this cohort of patients, guidance on differentiating between delirium, cancer related cognitive decline and neurocognitive disorder and some important considerations when it comes to decision-making ability in the context of cognitive decline. |
Journal of geriatric oncology | 2026 Nov 7 | PubMed |
| 06 |
Creative cognition in frontotemporal dementia and brain health.
View abstractCreative cognition is central to human thought and is affected by brain disease. Recent findings by Altmayer and colleagues link creative impairment in frontotemporal dementia to rostral prefrontal functional differentiation. These findings motivate a framework for investigating network coordination, circuit physiology, experience-dependent plasticity, and bodily and social regulation in creativity and health. |
Trends in neurosciences | 2026 Nov 7 | PubMed |
| 07 |
Initial antipsychotic prescription and all-cause mortality after claims-recorded dementia diagnosis in schizophrenia: A nationwide propensity-matched cohort study.
View abstractPURPOSE: To examine the association between an antipsychotic drug (APD) prescription recorded during the first 90 days after a claims-recorded dementia diagnosis and all-cause mortality in patients with schizophrenia. Secondary analyses compared APD generation and study-defined metabolic and QT-prolongation risk groups. METHODS: In this retrospective, nationwide, propensity-matched cohort study using Korean National Health Insurance Service data (2002-2022), the primary analysis included 28,506 patients with schizophrenia who received a qualifying claims-recorded dementia diagnosis (14,253 matched pairs). APD exposure was defined by prescriptions recorded during the first 90 days after the index diagnosis. Separate propensity-matched secondary cohorts compared first- and second-generation antipsychotics (FGAs and SGAs) and SGA metabolic- and QT-prolongation-risk groups. All-cause mortality was analyzed using Cox proportional-hazards models. RESULTS: In the primary matched cohort, mortality did not differ significantly between patients with an APD prescription during the initial 90-day window and those without a recorded prescription during that window (adjusted hazard ratio [aHR] 0.976, 95% confidence interval [CI] 0.939-1.015; p = 0.2228). Mortality also did not differ significantly between SGA and FGA users (aHR 1.018, 95% CI 0.946-1.095; p = 0.6291). In secondary analyses, mortality was significantly higher in the higher-metabolic-risk SGA group than in the lower-risk group (aHR 1.238, 95% CI 1.105-1.388; p = 0.0002) and in the higher-QT-prolongation-risk SGA group than in the lower-risk group (aHR 1.109, 95% CI 1.019-1.207; p = 0.0164). CONCLUSIONS: Among patients with schizophrenia who survived the 90-day classification window, an APD prescription recorded during the first 90 days after a claims-recorded dementia diagnosis was not significantly associated with adjusted all-cause mortality compared with no recorded prescription during that window. Secondary analyses showed higher mortality in the study-defined higher-metabolic- and higher-QT-risk SGA groups than in their lower-risk comparators. These observational associations do not establish comparative treatment safety or imply sustained use or non-use beyond the initial 90-day window. |
Progress in neuro-psychopharmacology & biological psychiatry | 2026 Nov 7 | PubMed |
| 08 |
Optimizing cognitive and behavioural recovery after stroke: clinical integration of dietary supplements with a focus on ω-3 fatty acids.
View abstractStroke remains a leading cause of long-term disability worldwide, with many survivors experiencing persistent cognitive and behavioural impairments despite advancements in acute management. Post-stroke neurorecovery is often incomplete, contributing to dementia, depression, and reduced quality of life, particularly in low- and middle-income settings where access to advanced rehabilitation and therapeutics is limited. This highlights an urgent need for accessible, adjunctive strategies that can enhance functional recovery. Emerging preclinical evidence indicates that dietary supplements can modulate key biological processes underlying neurorecovery, including neuroplasticity, neuroinflammation, oxidative stress, mitochondrial function, and synaptic remodeling. In this narrative review, we examine the role of major classes of nutraceuticals such as omega-3 fatty acids, vitamins, minerals, polyphenols, and amino acids in supporting cognitive and behavioural recovery after stroke with particular emphasis on omega-3 fatty acids, given their central role in neuronal membrane integrity, lipid-mediated signaling, and resolution of inflammation. We integrate mechanistic insights with preclinical and clinical data explicitly highlighting that theoretical models and basic research demonstrate significant promise, while current clinical evidence remains heterogeneous and frequently inconclusive. We discuss how dietary supplementation might be strategically incorporated alongside conventional rehabilitation paradigms including physiotherapycognitive training, and pharmacotherapy. We further highlight emerging concepts such as the gut-brain axis, precision nutrition, and biomarker-guided interventions, which are shaping the future of personalized neurorehabilitation. Ultimately, while dietary supplements offer a promising, cost-effective and accessible adjunctive approach. their current clinical utility is constrained by mixed translational efficacy. Overcoming these limitations will require rigorous patient selection, optimized timing, and shift towards evidence-based personalized, multimodal strategies. This will be essential to fully harness their therapeutic potential in improving cognitive and behavioural outcomes in stroke recovery. |
Neurochemistry international | 2026 Nov 7 | PubMed |
| 09 |
Single-cell and spatial transcriptomic insights into neural substrates of Behavioural dysfunction in Alzheimer's disease.
View abstractThe transition from bulk-tissue profiling to single-cell and spatially resolved transcriptomics has reshaped our understanding of Alzheimer's disease (AD) from a passive proteinopathy to a coordinated multicellular process spanning the neurovascular unit. However, translating these molecular catalogues into disease-modifying therapies requires a framework that links cellular transitions to neural circuit dysfunction and behavioural abnormalities. This review synthesizes the multicellular landscape of AD, tracing how cell-state-specific remodelling drives network collapse and cognitive decline. Neuronally, selective vulnerability targets projection networks and subclass-specific inhibitory interneurons. Their transcriptional silencing compromises projection pathways, including the entorhinal-hippocampal perforant path, disrupts cortical microcircuits, and underlies episodic memory impairment, hyperexcitability, and executive control failure. This neuronal degeneration is dynamically coupled to reactive glial and vascular remodelling across distinct spatial niches. We examine the non-linear transition of homeostatic astrocytes and microglia into specialized, plaque-associated reactive sub-states, as well as paracrine signalling decay at the neurovascular interface. Compromised capillary tight junctions and the shedding of pericytic survival receptors are proposed to promote blood-brain barrier disintegrity, triggering a feed-forward neuroinflammatory cascade of complement-mediated synaptic pruning. Crucially, we establish a three-tiered hierarchy of evidence, rigorously distinguishing cross-sectional, associative human postmortem findings from inferred functional trajectories in human cellular platforms, and causal, perturbation-based validations in transgenic rodent models. We review how contemporary multi-scale integration-combining single-nucleus transcriptomics with functional electrophysiological platforms and biophysical connectomic modelling-bridges the gap between terminal postmortem signatures and living brain dynamics. Finally, we outline a coordinated translational roadmap illustrating how spatially resolved cell-state networks can guide the development of fluid and imaging biomarkers, support biologically informed patient stratification, enrich clinical trials, and accelerate the development of circuit-restoring precision therapies, thereby providing a mechanistic framework that links cell-state transitions to neural circuit dysfunction, behavioural impairment, and precision medicine in Alzheimer's disease. |
Molecular and cellular neurosciences | 2026 Nov 7 | PubMed |
| 10 |
Examining the Relationship Between Regional Vulnerability and Psychotic-Like Experiences in Adolescents: The Potential Mediating Role of Cognition.
View abstractBACKGROUND: Psychotic-like experiences (PLEs) are subclinical hallucinations or unusual thought content that, when distressing or persistent, signal heightened risk for psychosis spectrum disorders and cognitive impairments. METHODS: We used data from the Adolescent Brain Cognitive Development (ABCD) study (N = ∼11,800) to examine if structural brain deviations toward neuropsychiatric disorders, quantified using disorder-specific Regional Vulnerability Indices (RVIs), were associated with distressing PLEs at age 13-14, and whether cognition mediated these relationships. Cortical and subcortical RVIs were calculated for schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, Parkinson's disease, metabolic disorder, and 22q11.2 deletion syndrome. RESULTS: Linear mixed-effects models revealed that higher cortical RVIs for schizophrenia, Alzheimer's disease, bipolar disorder, metabolic disorder, and Parkinson's disease-and all subcortical RVIs-were significantly associated with greater distressing PLE severity. Both cortical and subcortical RVIs were negatively associated with fluid and crystallized cognition, with subcortical RVIs showing the largest effects. Mediation analyses indicated that crystallized cognition, and to a lesser extent fluid cognition, mediated many RVI-distressing PLE relationships. DISCUSSION: These findings suggest that neuroanatomical differences confer risk for psychotic-like experiences partly through their impact on cognitive development. The results highlight RVIs as sensitive markers of distributed brain vulnerability in youth and suggest that cognitive function, particularly crystallized ability, is a potential pathway linking brain structural alterations to emerging psychotic symptoms. |
Biological psychiatry. Cognitive neuroscience and neuroimaging | 2026 Nov 7 | PubMed |
| 11 |
Cognitive leisure activity and incident dementia among older adults with diabetes: a 5-year prospective cohort study.
View abstractAIM: Exercise and physical activity are modifiable lifestyle factors for cognitive health, but whether cognitive leisure activity is also associated with dementia among older adults with diabetes is unclear. We examined its association with dementia incidence. METHODS: This 5-year prospective cohort included 779 adults aged ≥65 years with diabetes. Cognitive leisure activity was assessed using the cognitive activity scale and classified as lower (0-7 points) or higher (8-42 points). Incident dementia was identified from health and long-term care insurance records. Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for relevant baseline factors; a further model also adjusted for moderate-to-vigorous physical activity (MVPA). Sensitivity analyses used Fine-Gray models with death as a competing event. RESULTS: During a median follow-up of 5.0 years (IQR, 5.0-5.0), 112 participants developed dementia. After multivariable adjustment, higher cognitive leisure activity was associated with a lower hazard of incident dementia (HR, 0.615; 95% CI, 0.414-0.913). After additional adjustment for MVPA, the association remained similar (HR, 0.624; 95% CI, 0.419-0.929). Findings were similar when cognitive leisure activity was modeled continuously. In competing-risk analyses, the subdistribution HR was 0.667 (95% CI, 0.455-0.977) after additional adjustment for MVPA. CONCLUSION: Among older adults with diabetes, higher cognitive leisure activity was associated with lower 5-year dementia risk after accounting for baseline cognitive function, cardiometabolic factors, and measured physical activity, including walking in sensitivity analyses. Cognitive leisure activity may complement other lifestyle factors supporting cognitive health in this population. |
Diabetes & metabolism | 2026 Nov 7 | PubMed |
| 12 |
Efficacy and safety of anti-tau drugs for Alzheimer's disease: A systematic review and network meta-analysis.
View abstractOBJECTIVE: To evaluate and compare the effects of different anti-tau drugs on clinical and biological outcomes in patients with Alzheimer's disease (AD). METHODS: PubMed, Cochrane Library, and Embase databases were searched for identifying randomized, controlled clinical trials from inception to December 2025. RESULTS: Twelve high-quality studies with 11 drugs were evaluated. Systematic meta-analysis did not demonstrate significant efficacy of anti-tau drugs in preventing cognitive and functional declines or clearance of tau deposition on PET. However, effects in reducing levels of p-tau (SMD=-0.48, 95% CI: -0.73 to -0.22, P < 0.01) and t-tau (SMD=-0.69, 95% CI: -0.94 to -0.45, P < 0.01) in the cerebrospinal fluid were observed. Network analysis revealed that MAPT and nicotinamide ranked highest for improving cognitive function, and gosuranemab ranked highest for tau biomarker changes. CONCLUSION: The current findings highlight the disease-modifying potential of anti-tau therapies for AD, although clinical benefit is limited. The observed reductions in CSF tau biomarkers and the favourable safety profile of current anti-tau therapies suggest promising therapeutic potential for the treatment of AD. However, the clinical value of anti-tau therapies should be confirmed in adequately powered phase III trials with biomarker-enriched populations. |
The journal of prevention of Alzheimer's disease | 2026 Nov 7 | PubMed |
| 13 |
Exploring remembering through embodied geographies, walking, and culturally relevant third places.
View abstractSocial reminiscence, or sharing memories in conversation with others, may improve memory recall. When paired with walking, social reminiscence becomes an exercise in collective, place-based memory reconstruction. We explore how culturally relevant third places, and experiences tied to place become embodied, contributing to collective memory-making and remembering among older adults with and without memory loss, and particularly for those living in gentrifying neighborhoods. Drawing from participatory geography methods, the Sharing History through Active Reminiscence and Photo Imagery (SHARP) study in Portland and Seattle engages older Black adults in reminiscence while walking pre-planned routes that pass culturally meaningful locations, revealing how place, walking, and social reminiscence may contribute to remembering. Walking sessions were transcribed and categorized to identify sections constituting distinct memories. During and after the walking intervention, data were collected from 35 focus groups, coded thematically for reflections on memory, remembering, and place. Results suggest that collective remembering and emotion recall occur through social reminiscing while triadic walking. The three proposed pathways eliciting in-place memory and emotion responses through walking are: (1) sensory triggers, specifically visual images (2) recalling social actors associated with places (e.g., clergy, business people), and (3) experiencing feelings of place attachment. Findings also indicate that culturally relevant third places are potential spatial cues for recalling embodied memories of place when physical places no longer exist, given that gentrification can disrupt cognitive maps of place, rendering places harder to recall. Place-based walking methods may support positive cognitive outcomes (e.g., memory-making) facilitated through embodied spatial processes. |
Health & place | 2026 Nov 7 | PubMed |
| 14 |
A UHPLC-MS/MS method for the quantification of oxytocin in human saliva.
View abstractGiven the reported correlation between cerebrospinal fluid (CSF) and salivary oxytocin concentrations, salivary oxytocin has been proposed as a promising peripheral biomarker of central oxytocin activity. To date, oxytocin levels are commonly measured using enzyme immunoassays or radio-immunoassays; however, several challenges related to its accurate quantification have been reported, underscoring the need for a standardized and reliable analytical method. The present study aimed to develop and validate a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of oxytocin in human saliva, in accordance with EMA and FDA guidelines for bioanalytical method validation. Oxytocin levels were determined using the standard addition method. The chromatographic separation was performed through a gradient elution of two mobile phases (HO + 0.1% F.A. and MeOH: DMSO 97:3 (v/v) + 0.1% F.A.) using a Phenomenex Luna Omega 1.6 μm PS C18 100 Å LC Column 50 × 2.1 mm at 40°C with a column thermostat. It was connected to a tandem mass spectrometer, and the chromatographic run lasted 5 min. Additionally, in order to evaluate precision and accuracy of the method, real-world samples from caregivers working with people with dementia were analyzed. Method validation achieved satisfactory results in terms of robustness and reproducibility, especially at higher concentration values, while expected higher variability at lower concentrations was observed. However, real-world samples analysis confirmed the applicability of the method to real biological samples. Overall, the method was able to accurately quantify oxytocin levels in real-world samples, thus demonstrating its applicability in epidemiological studies. |
Psychoneuroendocrinology | 2026 Nov 6 | PubMed |
| 15 |
Trends in Antipsychotic Initiation and Use Among Adults With Dementia, 2016-2025: A Pharmacoepidemiologic Study Using the TriNetX Research Network.
View abstractOBJECTIVES: To examine prescribing trends in prevalence and initiation of individual antipsychotics among a predominantly US-based cohort of adults with dementia from 2016 to 2025, with demographic stratification and formal trend analysis. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: This study used TriNetX Research Network data from 111 health care organizations. Adults aged ≥65 years with dementia between January 1, 2016 and December 31, 2025 were included; individuals with prior psychotic disorders were excluded. METHODS: Eighteen Food and Drug Administration-approved antipsychotics, including 14 second-generation and 4 first-generation agents, were identified from electronic health record prescription data. Annual prevalence and initiation (proportion and rates) were calculated overall and by age, sex, and race. Joinpoint regression was used to estimate annual percent change (APC) and average APC in initiation. RESULTS: Among 950,573 patients with dementia (mean age, 82 years; 56.4% female), the prevalence of antipsychotic use increased from 2016 to 2025. Quetiapine and haloperidol were the most frequently used agents, increasing from 3605 to 18,432 and from 4745 to 15,829 per 100,000, respectively. Olanzapine prevalence increased from 1205 to 9264 per 100,000 patients. Initiation rates rose substantially, driven by select antipsychotics; quetiapine initiations increased nearly 5-fold, whereas olanzapine showed a steep increase (average APC, 30.51%; P < .001). Use was highest among individuals aged 75 to 84 years and varied by sex and race. Joinpoint analyses demonstrated late-period acceleration for several agents, including quetiapine, olanzapine, risperidone, and brexpiprazole. CONCLUSIONS AND IMPLICATIONS: Antipsychotic use in dementia increased substantially over the past decade, driven primarily by rising initiation of selected agents. These findings highlight marked agent-specific and demographic heterogeneity in prescribing patterns and underscore the need for continued monitoring of antipsychotic use in this high-risk population. |
Journal of the American Medical Directors Association | 2026 Nov 7 | PubMed |
| 16 |
Association of Cerebral Arteriosclerosis with Premortem Dementia Severity across Braak Stages.
View abstractINTRODUCTION: Cerebrovascular pathology often coexists with Alzheimer's disease neuropathologic change, but the association between cerebral arteriosclerosis and dementia severity may vary with neurofibrillary pathology. We examined this association across Braak stages in a large autopsy cohort. METHODS: We included 7,701 autopsy participants with cerebral arteriosclerosis ratings, Braak stage, and premortem Clinical Dementia Rating Sum of Boxes (CDR-SB). Multivariable linear regression estimated associations between moderate/severe versus none/mild arteriosclerosis and CDR-SB within Braak 0-II, III-IV, and V-VI strata, adjusting for demographic, genetic, and neuropathologic covariates. Interaction and sensitivity analyses were performed. RESULTS: Moderate/severe arteriosclerosis was present in 3,494 participants (45.4%). Its association with higher CDR-SB was strongest at Braak 0-II (β = 1.56, 95% CI 0.98 to 2.14, p < 0.001), weaker at III-IV (β = 0.89, 95% CI 0.33 to 1.45, p = 0.002), and not statistically significant at V-VI (β = 0.22, 95% CI -0.14 to 0.58, p = 0.223). The V-VI versus 0-II interaction contrast was significant (p = 0.029), but the joint 3-level interaction test was not (2 df; p = 0.085). The V-VI confidence interval remained compatible with a modest positive association. Low-Braak findings were consistent across sensitivity analyses. CONCLUSION: Moderate/severe cerebral arteriosclerosis was associated with greater premortem dementia severity, primarily among participants with low Braak stage, with attenuation at higher Braak stages. These findings suggest that the clinicopathologic relevance of cerebral arteriosclerosis may be more apparent when Alzheimer-type neurofibrillary pathology is limited. |
Dementia and geriatric cognitive disorders | 2026 Nov 7 | PubMed |
| 17 |
The hepatic secretome-microglia axis in huntington's disease: Linking peripheral metabolic dysfunction to neuroinflammation and novel therapeutic opportunities.
View abstractHuntington's disease (HD) is traditionally regarded as a progressive neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene, resulting in selective striatal neuronal degeneration and progressive motor, cognitive, and psychiatric impairment. However, accumulating evidence indicates that HD is a systemic disorder involving profound metabolic, mitochondrial, and immune dysfunction in peripheral organs, particularly the liver. Emerging studies suggest that hepatic mitochondrial dysfunction induced by mutant huntingtin remodels the hepatic secretome through altered secretion of hepatokines, extracellular vesicles, complement proteins, inflammatory cytokines, and metabolic mediators. These circulating factors may disrupt blood-brain barrier integrity, promote microglial immunometabolic reprogramming, enhance complement-mediated synaptic pruning, and amplify chronic neuroinflammation, thereby accelerating neurodegeneration. This review summarizes current evidence supporting the liver-brain axis in HD and discusses how hepatic metabolic dysfunction contributes to central nervous system pathology. Furthermore, we highlight therapeutic strategies aimed at restoring hepatic mitochondrial homeostasis, modulating hepatokines, extracellular vesicles, exosomal microRNAs, and complement signaling to interrupt pathological liver-to-brain communication. Finally, we discuss emerging translational approaches, including multi-omics technologies, engineered extracellular vesicles, gene-editing platforms, and precision medicine, that may facilitate the development of disease-modifying therapies. By integrating peripheral metabolic regulation with central neuroimmune mechanisms, this review presents the hepatic secretome microglia axis as a potential conceptual framework for understanding HD pathogenesis and identifies liver targeted interventions as promising therapeutic opportunities beyond conventional neuron centric strategies. |
Metabolic brain disease | 2026 Nov 7 | PubMed |
| 18 |
Effectiveness of Verbal Fluency Tests for Detecting Cognitive Decline in Adults with Alzheimer's Dementia and Frontotemporal Dementia: A Three-Level Meta-Analysis.
View abstractAs our population ages, the prevalence of dementia, including Alzheimer's dementia (AD) and frontotemporal dementia (FTD), is increasing. Early dementia diagnoses facilitate access to interventions when they are most effective for prolonging and improving life. Verbal fluency tests (e.g., FAS and Animal Fluency) can aid in the diagnosis of AD and FTD through detecting declines in executive functioning and language. These tests may be particularly useful for diagnosing the behavioural variant of FTD (bvFTD), which is associated with declines in executive functioning. A systematic search of Embase, PsycINFO, PubMed, MEDLINE, CINHAL, and AgeLine identified 127 peer-reviewed studies published from January 2010 to July 2024, which compared FAS and Animal Fluency Test performances of people with AD or FTD to cognitively-healthy controls. Hedges' g effect sizes determined the effectiveness of three common score types (Total, Intrusion, Perseveration) for AD/FTD combined, AD and combined FTD subtypes, and AD and FTD subtypes (e.g., bvFTD). FAS and Animal Fluency Total Scores were the most reported and effective for detecting cognitive decline in these dementias combined (g = -1.31 and g = -1.95, respectively), but similar effects were seen for AD and bvFTD. The pattern of effects was not influenced by patient characteristics and remained consistent when only low risk-of-bias studies were analysed. However, significant publication bias may have inflated the effects for AD. Overall, the FAS and Animal Fluency Total Scores can effectively detect cognitive decline in both AD and FTD, although they cannot be recommended for differentiating between AD and bvFTD. |
Neuropsychology review | 2026 Nov 7 | PubMed |
| 19 |
GLP-1 receptor agonist use in patients with minor stroke is associated with lower risk of post-stroke dementia.
View abstractBACKGROUND: Minor ischemic stroke is associated with increased risks of post-stroke dementia independent of stroke recurrence, yet there are no guideline-recommended therapies targeted at cognitive outcomes. Glucagon-like peptide - 1 receptor agonists (GLP-1RAs) have been shown to be associated with lower risk of dementia among diabetes patients; however, their effect on cognitive outcomes among minor stroke patients is largely unknown. METHODS: This retrospective cohort study used de-identified electronic health record data from the TriNetX US Collaborative Network (2016-2025). Adult patients with minor ischemic stroke (NIHSS ≤ 5 and non-disabling) were included. Patients with prior intracranial hemorrhage, mood disorders, anxiety disorders, cognitive impairment, or dementia were excluded. GLP-1RA use was defined as a prescription prior to or within 3 months of stroke diagnosis. After 1:1 propensity score matching on 75 baseline characteristics, outcomes were assessed over a 5 year follow-up using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: After propensity score matching, 1,425 patients per group were analyzed. Mean age was 60.7 years, with diabetes present in 92.7% and mean HbA1c of 8.7%. GLP-1RA use was associated with a 48% lower hazard of post-stroke dementia (3.4% vs. 7.0%, HR 0.52 [95% CI 0.37-0.74]) and a 31% lower hazard of other neurocognitive complaints (17.2% vs 25.6%, HR 0.69 [95% CI 0.59-0.81]) over 5 years. GLP-1RA use was also associated with reduced mortality (4.4% vs. 8.8%; HR 0.57 [95% CI 0.42-0.77]) and major ischemic stroke (1.5% vs. 2.7%; HR 0.59 [95% CI 0.35-1.01]). No significant difference in intracranial hemorrhage rates was observed. CONCLUSIONS: Among this cohort of minor ischemic stroke patients mostly with concomitant diabetes, GLP-1RA use was associated with significantly reduced risks of post-stroke dementia and other neurocognitive complaints. These findings support prioritizing GLP-1RA use for diabetic patients who suffered minor ischemic stroke. Prospective trials are warranted to confirm causality and determine optimal implementation. |
Journal of neurology | 2026 Nov 7 | PubMed |
| 20 |
Impact of Statin and Aspirin Use on Dementia Diagnosis Stratified by Cardiovascular Risk.
View abstractBACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) and Alzheimer's disease (AD) dementia share common risk factors. However, the role of ASCVD prevention therapies in AD dementia prevention is not fully understood. We examined the effect of LLT and antiplatelets with dementia and AD dementia diagnoses across ASCVD risk profiles. METHODS: We used data from primary prevention registry derived from a large healthcare network. Multivariable Cox proportional models were generated to study dementia and AD dementia diagnoses, stratified by ASCVD risk profiles. Impact of aspirin and LLT use on dementia and AD dementia diagnoses was assessed in adjusted models. RESULTS: Among n= 347,128, 2.4% developed dementia and 2.0% developed AD dementia over a median follow-up of 7.94 years. In adjusted models, dementia (HR, 2.59; 95% CI [2.29-2.92]) and AD dementia (HR, 2.85; 95% CI [2.49-3.25]) was higher in high risk patients. Low and high-dose aspirin among high ASCVD risk had lower dementia (HR, 0.88; 95% CI, [0.77-1.00] and HR, 0.83; 95% [CI 0.77-0.90]) and AD dementia (HR, 0.83; 95% CI [0.77-0.91] and HR, 0.85; 95% CI [0.73-0.97]). Similarly, moderate- to high-dose LLT use among high ASCVD risk groups was associated with lower dementia (HR, 0.85; 95% CI [0.79-0.93]) and AD dementia (HR, 0.85; 95% CI [0.78-0.93]). CONCLUSIONS: Higher baseline ASCVD risk was associated with increased risk of dementia and AD dementia diagnoses. Aspirin and moderate- to high-dose LLT use among patients with high ASCVD risk was associated with lower dementia and AD dementia risk. |
Journal of the American Heart Association | 2026 Nov 7 | PubMed |
| 21 |
Reversible severe functional decline in an older patient with Alzheimer's dementia: A case report.
View abstractBACKGROUND: Enteral feeding via percutaneous endoscopic gastrostomy (PEG) is generally discouraged in advanced dementia, because it has not been shown to improve survival, aspiration risk, or functional outcomes. However, these recommendations assume accurate disease staging. Reversible conditions such as metabolic encephalopathy and severe malnutrition may mimic terminal-stage dementia, leading to premature limitation of potentially beneficial nutritional support. This case highlights the importance of individualized reassessment before concluding that enteral feeding is futile. CASE PRESENTATION: An 85-year-old woman with an 8-year history of Alzheimer dementia developed profound functional decline over 3-4 months, including mutism, inability to ambulate, incontinence, and minimal oral intake. At a routine visit with her primary care clinician (PCC), she was presumed to have progressed to advanced dementia, and no further evaluation was pursued, because current guidelines discourage artificially administered nutrition and hydration in advanced dementia. After transitioning to home-based primary care, her new PCC investigated the unusually rapid decline. Laboratory testing revealed severe hypernatremia (sodium, 158 mmol/L), acute kidney injury, and severe malnutrition (body mass index [BMI], 16.1). She was diagnosed with metabolic encephalopathy superimposed on moderate-stage Alzheimer dementia. Nutritional assessment confirmed severe malnutrition by Global Leadership Initiative on Malnutrition (GLIM) criteria. Following transdisciplinary evaluation and shared decision-making with the patient's daughter, her designated health care proxy, PEG placement was performed. Nutritional rehabilitation normalized laboratory values, restored BMI to 21-22, and resulted in marked cognitive and functional improvement. CONCLUSIONS: Severe malnutrition and metabolic derangements may produce a reversible syndrome that mimics advanced dementia. Careful evaluation of reversible contributors to rapid decline is essential before forgoing nutritional support, thus allowing for individualized, goal-concordant decisions and avoiding inappropriate therapeutic nihilism. |
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition | 2026 Nov 7 | PubMed |
| 22 |
Hormone Replacement Therapy and Cerebral Hemodynamics in Postmenopausal Women: A Systematic Review and Meta-Analysis.
View abstract: Hormone replacement therapy (HRT) has well-established effects on systemic vascular function in postmenopausal women, but its effects on cerebral hemodynamics remain poorly understood. This systematic review and meta-analysis evaluated the effects of HRT on ultrasound-based measures of cerebral hemodynamics. We hypothesized that HRT would be associated with reduced pulsatility index (PI), with stronger effects for estrogen-only formulations. : Embase, PubMed, Web of Science, and CENTRAL were searched following PRISMA guidelines (January 25, 2026). Studies reporting PI, resistive index (RI), and cerebral blood velocity (CBV) in postmenopausal women using HRT were included. Risk of bias was assessed using validated tools. Multilevel meta-analytic models using restricted maximum likelihood accounted for dependency among effect sizes. Separate models examined between-group and within-individual comparisons. Moderator analyses examined hormone formulation and administration route. Thirty-eight studies (27 meta-analyzed) were included. HRT was associated with lower PI versus controls, with a pooled mean difference of -0.051, 95% CI [-0.089, -0.012], p=0.009, k=31. Within-individual analyses demonstrated a reduction in PI over time, with a pooled mean change of -0.049, 95% CI [-0.081, -0.015], p=0.004, k=55. RI and CBV were not significantly altered (RI: p=0.74, CBV: p=0.54). Estrogen-only regimens were associated with greater reductions in PI than estrogen plus progestin or tibolone, while route of administration demonstrated no consistent effects. Between-study heterogeneity was substantial. : HRT was associated with reduced cerebrovascular pulsatility, suggesting a physiological effect on cerebral circulation. However, substantial heterogeneity across studies limits conclusions regarding factors that may modify this response. |
Journal of applied physiology (Bethesda, Md. : 1985) | 2026 Nov 7 | PubMed |
| 23 |
Two decades of progress in C4-unsubstituted3-acetylcoumarins: synthesis, reactivity, heterocyclic diversity, and applications.
View abstractC4-unsubstituted 3-acetylcoumarins represent a versatile class of coumarin-based heterocycles that combine a reactive acetyl group at the C-3 position with an accessible C4-H site. This structural arrangement makes them valuable synthons for functionalization, annulation and the construction of diverse heterocyclic frameworks. This review summarizes the progress reported from 2006 to 2026 in the synthesis, reactivity and applications of C4-unsubstituted 3-acetylcoumarin derivatives. The main synthetic strategies include Knoevenagel condensation, diketene-based routes, alkynoate-mediated synthesis, hydrodehalogenation, cross-dehydrogenative coupling and carbonyl-alkyne metathesis. Their reactivity covers halogenation, reduction, thionation, phosphorylation, Mannich reactions, condensation with nitrogen nucleophiles, C-H functionalization and cycloaddition reactions. These transformations provide access to a broad range of coumarin-containing heterocycles, including pyrazoles, thiazoles, oxazoles, isoxazoles, pyridines, pyrimidines, thiophenes, triazoles, quinoxalines, diazepines and fused polycyclic systems. Beyond synthetic chemistry, many derivatives show promising biological activities, including antibacterial, antioxidant, anti-inflammatory, anti-Alzheimer, antitumor, antidiabetic and enzyme-inhibitory effects. Their photophysical properties have also enabled their application as fluorescent chemosensors for ions, reactive species and biologically relevant molecules. Finally, this review highlights future opportunities in greener synthesis, structure-activity relationship analysis and advanced biological evaluation. |
RSC advances | 2026 Nov 6 | PubMed |
| 24 |
SGLT-2 Inhibitors versus GLP-1 Receptor Agonists for Dementia and Depression in Type 2 Diabetes Mellitus: A Meta-Analysis.
View abstractBACKGROUND: The comparative effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on dementia and depression risk in patients with type 2 diabetes mellitus (T2DM) remain unclear. We conducted a meta-analysis to directly compare the incidence of dementia and depression-related outcomes between users of these two drug classes. METHODS: A systematic literature search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from inception to June 1, 2026. Observational studies reporting quantifiable data on dementia or depression-related events in adults with T2DM were included. Detailed information on study design, age, demographic characteristics, eligibility criteria, outcome definitions, and outcome incidence was extracted. Data were pooled using a random-effects model to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity analyses involved sequential exclusion of individual studies. Prespecified subgroup analyses examined effect modifiers including geographic region, study design, age, and follow-up duration. Study quality was assessed using the Newcastle-Ottawa Scale, and the overall certainty of evidence and methodological rigor of this meta-analysis were evaluated using the AMSTAR 2 checklist. RESULTS: Thirteen observational studies comprising 1,055,315 participants were included. Compared with GLP-1RA users, SGLT-2i users had lower rates of all-cause dementia (OR 0.85, 95% CI 0.77-0.94; P = 0.001), vascular dementia (OR 0.75, 95% CI 0.71-0.80; P < 0.001), Alzheimer's disease (OR 0.76, 95% CI 0.72-0.79; P < 0.001), and composite depression-related outcomes (OR 0.76, 95% CI 0.67-0.88; P = 0.001), including suicide/self-harm (OR 0.69, 95% CI 0.60-0.80; P < 0.001) and depression/anxiety (OR 0.78, 95% CI 0.65-0.93; P = 0.006). Subgroup analyses revealed more pronounced differences in Asian populations (dementia: OR 0.86, 95% CI 0.75-0.99; I = 0%), European cohorts (depression: OR 0.67, 95% CI 0.54-0.84; I = 83%), and in studies that enrolled younger adults (minimum age 18 years, without an upper age restriction) (dementia: OR 0.79, 95% CI 0.76-0.81; I = 0%; depression: OR 0.67, 95% CI 0.54-0.84; I = 83%). CONCLUSIONS: In this meta-analysis of observational studies, SGLT-2i use was associated with lower rates of dementia and depression-related outcomes compared with GLP-1RA use in patients with T2DM. Age and geographic region may influence the observed associations. Future randomized controlled trials and studies reporting outcomes stratified by sex, socioeconomic status, and educational level are warranted. |
Diabetes, metabolic syndrome and obesity : targets and therapy | 2026 | PubMed |
| 25 |
Safety-First, Severity-Adapted Enhanced Recovery After Surgery for Patients with Neurodegenerative Disorders: A Narrative Review and Proposed Framework.
View abstractEnhanced Recovery After Surgery (ERAS) pathways have been shown to improve perioperative outcomes in broad surgical populations. However, their safety, feasibility, and optimal adaptation remain uncertain in patients with neurodegenerative disorders (NDDs), particularly those with dementia and Parkinson's disease. These patients often present with cognitive impairment and disability, which pose major perioperative care challenges. Our narrative review elucidates the pathophysiological traits, perioperative risks, and medication-related complications of patients with NDDs. We determine potential risks related to standard ERAS components, outline important drug-drug interactions between frequently prescribed NDD medications and anesthetic agents. We also offer useful suggestions for preoperative evaluation, intraoperative management, postoperative recovery, and post-discharge rehabilitation. We then present a three‑tier severity‑adapted ERAS framework, in which patients are stratified into mild, moderate, or severe groups based on the Hoehn and Yahr staging scale for Parkinson's disease and the Clinical Dementia Rating for dementia. This framework provides recommendations for the retention, modification, or restriction of ERAS components. We postulate that in this vulnerable population, the stratified decision-making pathways may help preserve the benefits of enhanced recovery while reducing avoidable iatrogenic harm and improving clinical feasibility. This, however, represents a conceptual framework requiring prospective validation. |
Clinical interventions in aging | 2026 | PubMed |
| 26 | Undiagnosed dementia in underserved African American populations: Missed opportunities for care. | International psychogeriatrics | 2026 | Scholar |
| 27 | Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation | Alzheimer's Research & Therapy | 2026 | Scholar |
| 28 | Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA) | medRxiv | 2026 | Scholar |
| 29 | Decreased Length of Locus Coeruleus Norepinephrine Axons and Increased Amyloid Beta Pathology in Male APP/PS1 Mice During Protracted Abstinence From Alcohol | Neurotoxicity Research | 2026 | Scholar |
| 30 | Causes of death in patients with dementia: A study in a geriatric hospital in São Paulo, Brazil | Journal of Alzheimer's Disease | 2026 | Scholar |

